The insulin-like growth factor pathway (IGF) has been implicated in prostate development and carcinogenesis. We conducted a comprehensive analysis, utilizing a resequencing and tagging SNP approach, between common genetic variation in the IGF1, IGF binding protein (BP) 1 and IGFBP3 genes with IGF-I and IGFBP-3 blood levels, and prostate cancer (PCa) risk, among Caucasians in the NCI Breast and Prostate Cancer Cohort Consortium. We genotyped fourteen IGF1 single-nucleotide polymorphisms (SNPs) and sixteen IGFBP1/IGFBP3 SNPs to capture common (MAF ≥5%) variation among Caucasians. For each SNP, we assessed the geometric mean difference in IGF blood levels (N=5,684) across genotypes and the association with PCa risk (6,012 PCa cases/6,641 controls). We present two-sided statistical tests and correct for multiple comparisons. A nonsynonymous IGFBP3 SNP in exon1, rs2854746 (Gly32Ala), was associated with IGFBP-3 blood levels (P adj =8.8x10 -43 ) after adjusting for the previously established IGFBP3 promoter polymorphism A-202C (rs2854744); IGFBP-3 blood levels were 6.3% higher for each minor allele. For IGF1 SNP rs4764695, the risk estimates among heterozygotes was 1.01 (99%CI: 0.90-1.14) and 1.20 (99%CI: 1.06-1.37) for variant homozygotes with overall PCa risk. The corrected allelic P-value was 8.7x10 -3 . IGF-I levels were significantly associated with PCa risk (P trend =0.02) with a 21% increase of PCa risk comparing the highest quartile to the lowest quartile. We have identified SNPs significantly associated with IGFBP-3 blood levels, but none of these alter PCa risk; however a novel IGF1 SNP, not associated with IGF-I blood levels, shows preliminary evidence for association with PCa risk among Caucasians.
Introduction
The role of the insulin-like growth factor (IGF) pathway has been studied extensively in both normal and transformed cells. Both in vivo (1) (2) (3) and in vitro (4) (5) (6) studies demonstrate that IGF-I binding to the IGF type 1 receptor modulates cellular proliferation, differentiation and apoptosis -important characteristics in tumorigenesis (7) (8) (9) (10) (11) . Circulating levels of IGF-I derive mostly from the liver; over 90% is complexed with IGF-binding protein 3 (IGFBP-3) and an acid-labile subunit thus reducing bioavailability (12, 13) . However, many types of tissues, including certain neoplasms (10) , are capable of producing IGF-I locally. Although the main effect of IGFBP-3 is thought to be inhibition of cell growth and proliferation due to sequestration of the IGF-I ligand, recent research suggests IGFBP-3 has antiproliferative and proapoptotic effects independent of IGF-I (14, 15) .
Elevated blood levels of IGF-I have been associated with several cancers, most commonly with prostate cancer (PCa), although later studies have found weaker associations than initially reported (16) (17) (18) (19) (20) (21) (22) (23) . A recent meta-analysis of twelve prospective studies reported a 38% increased risk of developing PCa when comparing the highest to lowest quartile of IGF-I levels (24) . Although circulating IGFBP-3 levels were inversely associated with PCa risk in earlier studies, recent findings have been mostly null (23) (24) (25) (26) (27) .
Nutrition remains a key determinant of circulating IGF-I levels (28, 29) , but heritability studies have estimated that the proportion of variance explained by inherited genetic variation ranges from 38% to >80% for IGF-I and IGFBP-3 blood levels (30) (31) (32) (33) (34) . The specific genetic variants that contribute to heritable risk are not well defined. Results between an upstream IGF1 repeat sequence (CA) n and IGF-I blood levels have varied (35) (36) (37) (38) , most studies, including a recently published meta-analysis (39) , have reported a null association (40) (41) (42) (43) (44) . In a case-control study, Johansson et al. recently reported a marginally significant association (P=0.02) between an IGF1 haplotype, previously reported associated with PCa risk (45) , and IGF-I blood levels among controls in the Cancer Prostate in Sweden (CAPS) study (46) ; however, the authors were unable to replicate this haplotype-IGF-I association in a prospective study. In contrast, the significant decreased IGFBP-3 blood levels among carriers of the C allele of the IGFBP3 A-202C promoter polymorphism (rs2854744) has been observed across multiple studies of both men and women (39, 41, 43, (47) (48) (49) (50) (51) (52) (53) (54) . Additionally, an in vitro transient transfection assay demonstrated the C allele had 50% lower activity than the A allele (55) .
Most previous genetic studies of the IGF1 locus with PCa risk have focused on an upstream IGF1 (CA) n repeat with equivocal results (56) (57) (58) (59) (60) . Recently, two investigations comprehensively examined IGF1 genetic variation with PCa risk selecting SNPs by public databases (i.e. HapMap), exonic resequencing, or both. In the Multiethnic Cohort (MEC) study Cheng et al. identified an association with an upstream IGF1 SNP (rs7965399) and PCa (61) , while in the CAPS study, Johannsson et al. used public databases reported a significant increased risk of PCa for single-copy carriers of an IGF1 haplotype spanning intron 2 through the 3'UTR (45) . The relationship between common genetic variation in the IGFBPs and PCa risk has only been thoroughly examined by Cheng et al. in the MEC; no association was found between IGFBP1 and IGFBP3 polymorphisms with PCa risk (62) .
We conducted a comprehensive haplotype tag-SNP analysis of the common genetic variation in IGF1, IGFBP1 and IGFBP3 in relation to IGF-I and IGFBP-3 blood levels and PCa risk among Caucasians in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3), a pooled nested case-control study from seven cohorts (63) . The large sample size of the BPC3 having 6,012 prospective PCa cases and 6,641 controls allows us to detect modest genetic effects and assess effect modification. In addition, we are able to examine risk in clinically important subgroups of PCa defined by stage and Gleason score at diagnosis.
Results
Characteristics of the studies within the BPC3 are presented in Table 1 . Briefly, the cases and controls were comparable across cohorts with respect to demographic and other potentially PCa-related factors, with the exception of height where the ATBC Study (Finnish population) and EPIC cohorts (8 European countries) are shorter in stature. Family history was not available for the EPIC and PHS cohorts. PCa clinical information such as stage (63%) and Gleason score (56%) was available for over half of the cases.
The IGF1 locus was characterized by four haplotype blocks ( Figure 1, bottom panel) . The IGFBP1 and IGFBP3 loci are near each other, separated by 19-kb, and were characterized by three haplotype blocks defined by 12 htSNPs (Figure 2-bottom 
IGF1 Genetic Variation and IGF-I Blood Levels
Individual cohort and pooled values of log-transformed IGF-I blood levels were similar as were the case and control levels within each cohort (Supplementary Figure 1) . In a pooled analysis, 3 of 14 htSNPs were nominally associated with IGF-I blood levels ( Figure 1 : green triangles): rs35767 (Block 1; P uncorr =7.9x10 -3 ), rs12821878 (Block 2; P uncorr =1.0x10 -3 ) and rs1549593 (Block 3; P uncorr =3.3x10 -3 ). As shown in Figure 1 , the pair-wise LD for these three markers is negligible except between rs12821878 and rs1549593 (r 2 =0.27 among PLCO controls). The geometric means and 95%CIs by SNP and haplotypes are presented in Supplementary   Tables 3 and 4 . After correcting for multiple-comparisons, none of the IGF1 markers associations remained statistically significant (P corr >0.07) with IGF-I blood levels.
IGFBP1/IGFBP3 Genetic Variation and IGFBP-3 Blood Levels
The distributions of IGFBP-3 blood levels were not as uniform as IGF-I blood levels across the cohorts (Supplementary Figure 2) . Within each cohort, case and control blood levels of IGFBP-3 were very similar.
The geometric means and 95%CIs by SNP and haplotypes are presented in Supplementary and rs2854744 (A-202C) showed a consistent result such that across the three genotypes for rs2854746, the mean IGFBP-3 blood levels remained unchanged by rs2854744 (A-202C) genotypes (Table 2) . However, the differences in mean IGFBP-3 blood levels were statistically significant across rs2854746 in the heterozygote (CA) and variant homozygote (AA) strata defined by rs2854744 (A-202C) genotypes (P CA =2.7x10 -6 ; P AA =4.1x10 -6 ).
IGF1 Genetic Variation and Prostate Cancer Risk
The associations between the fourteen IGF1 htSNPs and overall PCa risk among Caucasians are presented in the upper panel of Figure 1 (red circles). The tests for heterogeneity (Supplementary Table 7) across cohorts were not statistically significant, thus we present the pooled results for the main effect analyses.
We found nominally significant associations between IGF1 SNPs rs2373722 (P uncorr =2.0x10-
3
) and rs4764695
(P uncorr =1.2x10 -4 ) with overall PCa risk (Supplementary Table 8 ). After controlling for multiple comparisons, the corrected p-value for rs2373722 was no longer significant (P corr =0.14), whereas rs4764695 remained statistically significant (P corr =8.7x10 -3 ). For rs4764695, the overall risk estimate was 1.01 (99%CI: 0.90-1.14)
for heterozygotes and 1.20 (99%CI: 1.06-1.37) for variant homozygotes, with consistent point estimates for heterozygotes and variant homozygotes across the cohorts ( Figure 3 ). The results remained unchanged when previously published data from the MEC were excluded from the analysis (P uncorr =2.8x10 -4 ; Supplementary Table 8 ). IGF1 marker rs4764695 was not significantly associated with IGF-I blood levels. Testing for effect modification by several variables of interest (family history of PCa, age at diagnosis, BMI, and height) revealed no statistically significant heterogeneity in any of the subgroup analyses for the 14 htSNPs (data not shown).
We examined the risk association of each SNP stratified by stage at diagnosis (High Stage: C or D;
Low Stage: A or B) and Gleason score at diagnosis (High Grade: ≥8; Low Grade: <8) compared to controls (data not shown). Among the fourteen IGF1 SNPs, rs4764695 was the only marker remaining statistically significant (P uncorr <0.01) across all of the strata except for stage ( Figure 2 shows the results for overall PCa risk for the twelve htSNPs and four additional IGFBP1 and IGFBP3 SNPs (red circles). None of the 16 SNPs were nominally associated with PCa risk at the P uncorr <0.01
IGFBP1 & IGFBP3 Genetic Variation and Prostate Cancer Risk
level. The IGFBP3 markers significantly associated with blood levels were not associated with PCa risk. The cohort-specific results are presented in Supplementary Table 11 and the IGFBP1 and IGFBP3 SNP analyses with and without the previously reported MEC samples are available in Supplementary Table 12 . None of the tests for heterogeneity (by cohort) or effect modification (family history, age at diagnosis, BMI, and height in tertiles and quartiles) were statistically significant in any of the subgroup analyses (data not shown).
The haplotype frequencies within the MEC panel and by cohort are presented in Supplementary Several reasons may explain the lack of association between rs4764695 and IGF-I blood levels. First, the IGF-I measurements reflect systemic levels measured at a single time point prior to PCa diagnosis rather than tissue specific levels. Free IGF-I blood levels, unavailable across these studies, may be a more biologically relevant measure and impacted by rs4764695. Furthermore, the complexity of the IGF pathway is likely not entirely captured in these simple associations and a more complete pathway analysis is warranted. Since the rs4764695 marker lies ~34kb downstream of IGF1, this marker may be involved in another pathway entirely.
In addition, measurement error for both the genotypes and IGF-I blood levels would lead to non-differential misclassification and a bias towards the null. Lastly, the result for rs4764695 may be spurious, although we have taken steps by setting a stringent alpha level (0.01) and correcting for multiple comparisons.
We identified several IGFBP3 SNPs strongly associated with IGFBP-3 blood levels among Caucasians IGFBP3, we tested the independent effect of six correlated SNPs using a multi-marker model and determined that the most significant SNP was rs2854746, a nonsynonymous polymorphism in exon 1 (Gly32Ala). This is in contrast to the promoter polymorphism rs2854744 (A-202C) that has been extensively reported to be associated with IGFBP-3 levels (39, 41, 43, (47) (48) (49) (50) (51) (52) (53) (54) . This observation has been alluded to in two previous reports (50, 53), but could not be substantiated due to the limited sample sizes and strong LD between these two markers among Caucasians (r 2 =0.85 among Caucasian PLCO controls). Although each minor allele was associated with 6.3% higher IGFBP-3 blood levels on average, rs2854746 explains only 3.6% of the variation.
The lack of an association between rs2854746 and PCa risk, whereas a strong influence on IGFBP3 blood levels exists, supports a Mendelian randomization argument for no etiological effect of IGFBP-3 on incident risk of PCa (66, 67) . However caution is needed since confounding or pleiotropic effects would negate this argument (68).
The major strength of this study is the utilization of a large cohort consortium and a comprehensive approach to examine the genetic variation across three genes in the IGF pathway, a strong candidate in prostate carcinogenesis. Specifically, we have the ability to look at the effects of SNPs on pre-diagnostic blood levels as well as risk in the same set of subjects. Although our data in Caucasians limits the generalizability to other ethnic/racial groups, our large sample size allows us to present the overall risk estimates using a 99% CI, reducing the chance of both false-positive and false-negative results. In addition, we reduced the probability of a spurious association due to multiple hypothesis testing by applying a correction across all models, traits, and genetic markers. The IGF pathway is a complex system and we have limited our study to three primary genes.
Additional IGF pathway genes need to be investigated and a more comprehensive pathway analysis would be necessary.
While several genome-wide association scans (GWAS) have recently identified multiple susceptibility loci for PCa risk (69-77), only recently has an IGF variant (IGF2-rs7127900) been among them. The Cancer Genetic Markers of Susceptibility (CGEMS) GWAS is the only publicly available database to compare our IGF1 rs4764695 finding. Although rs4764695 was not present on the CGEMS platform, a proxy rs1980236
showed a similar effect, although not statistically significant (P=0.57). However, the PLCO study was the first In conclusion, a significant association between prostate cancer risk and an IGF1 SNP, rs4764695, was identified among Caucasians. Although this is a novel finding, the evidence is still preliminary and further confirmation is needed. The estimated population attributable risk for homozygotic variant carriers is ~5% due to the high frequency of the minor allele (G=49%). This variant could be of greater importance due to the potential for a stronger association with high tumor grade PCa. The association between rs4764695 and cancer is exclusive with prostate cancer as the association with breast cancer risk and this marker has been reported as null in the NCI BPC3 study (54) . Furthermore, we provide strong evidence for a novel association between IGFBP-3 blood levels and a nonsynonymous IGFBP3 marker in contrast to the previously reported IGFBP3 promoter polymorphism. Additional studies, such as fine mapping to determine the causal variant in IGF1 and the examination of additional genes in the IGF axis are needed. In summary, preliminary evidence implicates common genetic variation in the IGF1 locus with PCa risk. 
Materials and Methods

Study Population
The BPC3 and member cohorts have been described in detail elsewhere (81 (87) . These cohorts collectively include over 248,000 men with a blood sample.
The current study was restricted to individuals who self-reported as Caucasian and consists of 6,012
prospective PCa cases and 6,641 controls. Cases from other ethnic groups were contributed mostly from the MEC and had been reported on previously (53, 61, 62); we analyzed the data for Caucasians with and without the contribution from the MEC (457 cases and 452 controls) to assess the impact on the overall results.
Prospective PCa cases were identified through population-based cancer registries or self-reports confirmed by medical records, including pathology reports. The BPC3 data for PCa consists of a series of matched nested case-control studies within each cohort; controls were matched to cases on a number of potential confounding factors, including age, country, and region of recruitment. For the current analysis, PCa cases were matched to available controls by age in five year intervals, cohort, and country of residence for EPIC. A written informed consent was obtained from all subjects and each study was approved by the Institutional Review Boards at their respective institutions.
IGF-I and IGFBP-3 Blood Levels
Pre-diagnostic measurements of IGF-I and IGFBP-3 were available for six of the seven BPC3 cohort members (ATBC, EPIC, HPFS, MEC, PHS and PLCO; IGF-I: N=6,076; IGFBP-3: N=6,059) (16, (19) (20) (21) (22) (23) 53) .
Most blood samples in the CPS-II were collected post-diagnosis and therefore were only included in the Applied Biosystems, Inc.). Assay information is available at the MEC Genetics website (http://uscnorris.com/mecgenetics/CohortGCKView.aspx). For each assay, the concordance rate was 100% for 102 samples from the SNP500 Cancer project (http://snp500cancer.nci.nih.gov) (91) and inter-laboratory completion and concordance rates were greater than 99%, based on cross-laboratory assessment of 30 SNPs on 94 samples from the Coriell Biorepository (Camden, NJ). The internal quality of genotype data at each genotyping center was assessed by typing 5-10% blinded samples in duplicate or greater (depending on study).
Statistical Analysis
All statistical tests presented are two-sided and were conducted in SAS 9.0 (SAS Institute). Figures and multiple testing corrections were generated in the statistical program R (http://cran.r-project.org/). To account for multiple hypothesis testing, we applied the method implemented in P ACT , a flexible and efficient approach that adjusts for correlation between multiple traits, genetic markers, and models (92) . P ACT utilizes less computational time while maintaining the accuracy of permutation or simulation-based tests. Since multiple models and traits can be considered, the p-value corrections were computed simultaneously for blood levels and PCa risk across all 30 IGF1 and IGFBP1/IGFBP3 markers. A test of significance was set at the 0.01 level to minimize the chance of both false positive and false negative results (93, 94 significant SNPs identified from the univariate analysis to assess independent SNP effects within a gene.
Genetic Determinants of Prostate Cancer
The statistical methods used have been described previously (93, 96) . In brief, we used conditional logistic regression to estimate ORs and 99% CI for disease associated with genetic markers (SNP or haplotype). The matching factors in the conditional logistic regression were age (in five year intervals), cohort, and country within EPIC. We estimated the genotypic ORs for disease by using the most common genotype as the referent group for the SNP analyses. We estimated haplotype-specific ORs using an expectationsubstitution approach to account for haplotype uncertainty given unphased genotype data (97, 98) . To test the global null hypothesis of no association between IGF genetic variation and risk of PCa, we used a likelihood ratio test comparing a model with additive effects for each common haplotype (treating the most common haplotype as the referent) to the intercept-only model. We considered haplotypes with greater than 5% frequency in at least one cohort to be "common". All other haplotypes were excluded. 
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